```
1
                           REPORTER'S RECORD
                         VOLUME 2 OF 2 VOLUMES
 2
                TRIAL COURT CAUSE NO. D-1-GN-23-003616
 3
    LAZARO LOE, individually and
                                       IN THE DISTRICT COURT
    as parent and next friend of
    LUNA LOE, a minor; MARY MOE
 4
    and MATTHEW, individually
 5
    and as parent and next
    friends of MAEVE MOE, a
 6
    minor; NORA NOE,
    individually and as parent
    and next friend of NATHAN
    NOE, a minor; SARAH SOE and
 8
    STEVEN SOE, individually and
    as next friends of SAMANTHA
 9
    SOE, a minor; GINA GOE,
    individually and as parent
10
    and next friend of GRAYSON
    GOE, a minor; PFLAG, INC.;
    RICHARD OGDEN ROBERTS III,
11
    M.D., on behalf of himself
12
    and his patients; DAVID L.
    PAUL, M.D., on behalf of
                                       TRAVIS COUNTY, TEXAS
    himself and his patients;
13
    PATRICK W. O'MALLEY, M.D.,
    on behalf of himself and his
    patients; and AMERICAN
15
    ASSOCIATION OF PHYSICIANS
    FOR HUMAN RIGHTS, INC. d/b/a
16
    GLMA; HEALTH PROFESSIONALS
    ADVANCING LGBTQ+ EQUALITY,
17
    v.
18
    THE STATE OF TEXAS; OFFICE
19
    OF THE ATTORNEY GENERAL OF
    TEXAS; JOHN SCOTT, in his
20
    official capacity as
    Provisional Attorney
21
    General; TEXAS MEDICAL
    BOARD; and TEXAS HEALTH AND
22
    HUMAN SERVICES COMMISSION
                                      201ST JUDICIAL DISTRICT
23
24
           HEARING ON APPLICATION FOR TEMPORARY INJUNCTION
                     AND PLEA TO THE JURISDICTION
25
```

systematic reviews that covered them -- the systematic reviews that covered them, which in turn cited them, but I couldn't tell you by name. I couldn't cite the study off the top of my head -- such studies off the top of my head.

- Q. Isn't it true actually that all of the studies concluded in some form that the provision of gender-affirming medical treatment showed beneficial or positive effects for the adolescents treated?
- A. Those were different studies. Some of the studies, as I say, were investigating the harms with regard to specific physical parameters, and other studies other studies tried looking at the benefits, usually the mental health benefits. And the ones that looked at harms, again, the objective physiological parameters were indeed able to document the decreases in physical health, and it's the studies that were trying to look for potential benefits that were looking the mental health parameters, which some claimed and some did not claim that there were benefits. So I'm not as I say, I'm not exactly sure which study you're referring to. The studies of harms are usually distinct from the studies of benefits.
- Q. Sure. Dr. Cantor, I'm asking about what studies you're referring to because you never mentioned

any particular study, so I'm asking.

1

2

5

6

7

8

10

11

12

13

14

15

16

18

20

21

22

23

24

- No, I cited the studies quite thoroughly in my I'm just pointing out that I can't recall their names off the top of my head. If you're asking me to refer to my report to name them, I can do that.
- The cohort studies that you discussed pertaining to the mental health benefits for seeking to assess mental health benefits or efficacy of the provision of medical treatment for gender dysphoria in adolescents, these studies fall within the middle of the so-called ubiquitous pyramid of evidence that you discussed; is that right?
- They're cohort studies. Α. Yes.
- Is it your testimony that cross-sectional Ο. peer-reviewed studies based on survey data are not valid forms of evidence?
- Not for outcomes of interventions, no. 17 Α.
- Dr. Cantor, you support the provision of 0. 19 medical treatment for gender dysphoria in adults; is that correct?
  - That is correct. Α.
  - The evidence pertaining to the provision of Q. medical treatment for gender dysphoria in adults is of the same kind and level of evidence pertaining to the provision of medical treatment for gender dysphoria in

```
adolescents; is that right?
 1
 2
            It's of the same kind, but when the
   interventions are aimed at an adult body, the risks are
   lower.
 5
            You do not dispute that there are medical
       Ο.
 6
   treatments that are provided to adolescents for which
   there are no randomized controlled trials?
 7
 8
            Such -- such interventions exist, yes.
       Α.
   the basic decision-making process is risk to benefit.
   So when there is a low-risk intervention, then we --
10
   then it's permissible or it's legitimate to employ only
11
12
   low-quality evidence of benefit. But when it's a high
   risk of harm, such as sterilizing --
13
14
            Dr. Cantor --
       Ο.
            -- a child --
15
       Α.
16
                  THE COURT:
                             Hold on.
17
                  MR. GONZALEZ-PAGAN: I'm on limited time.
   I'm going to object --
18
19
                  THE COURT: Yeah.
                                     So Dr. Cantor, your
20
   attorney will have a chance to ask things in more
   detail, so if you could just stick to what
21
22
   Mr. Gonzalez-Pagan -- they're worried about time.
23
   only have a certain amount of time, each side.
24
   you can concentrate on just his question and answer
25
   that.
```